Register to the webinar:
Description
Access to pathogen data and the equitable sharing of related benefits have garnered significant attention across various international fora. At the 2024 Conference of the Parties (COP) in Colombia, State Parties to the UN Convention on Biological Diversity (CBD) decided that companies "directly or indirectly" benefiting from Digital Sequence Information (DSI) should contribute 1% of profits or 0.1% of revenue to the newly established Cali Fund. In parallel, negotiations on a Pandemic Agreement have been progressing over the past three years, with the establishment of the Pathogen Access and Benefit-Sharing (PABS) System emerging as one of the most contentious issues.
The CBD COP decision raises several legal and practical questions regarding its implementation, with potential implications for the Pandemic Agreement. This webinar will provide an opportunity to discuss its significance for PABS and explore possible links between the two instruments. The webinar will begin with a presentation of the CBD COP decision by the CBD Secretariat, followed by perspectives from the academia, pharmaceutical industry, and health equity. The session will also provide an opportunity for the audience to engage with experts from these fields ahead of the upcoming session of the Intergovernmental Negotiating Body (INB) on the Pandemic Agreement.
Speakers
- Charlotte Germain-Aubrey | Project Management Officer, Secretariat for the Convention on Biological Diversity
- Amber Hartman Scholz | Head of Science Policy Department at Leibniz Institute DSMZ
- Bart van Vooren |Partner - Life Sciences & Biodiversity/ABS at Covington & Burling LLP
- Viviana Munoz Tellez | Coordinator, Health, Intellectual Property and Biodiversity Programme, South Centre
Moderated by Adam Strobeyko | Swiss National Science Foundation Researcher, Global Health Centre, Geneva Graduate Institute
Organised by
